HLA-C and cancer: Beyond immune cells, PRC2 in cancer cells has been shown to maintain bivalency at MHC class I (MHC-I) antigen–processing genes and silence MHC-I expression in selective MHC-Ilo cancers (e.g., small cell lung cancer, neuroblastoma); targeting PRC2 can potentially enhance antitumor immunity by increasing MHC-I antigen presentation in this setting (29).